	US 12,104,183 B2
	DNase H activity of Neisseria meningitidis Cas9
Erik J. Sontheimer, Auburndale, MA (US); and Yan Zhang, Shrewsbury, MA (US)
Assigned to UNIVERSITY OF MASSACHUSETTS, Boston, MA (US)
Filed by UNIVERSITY OF MASSACHUSETTS, Boston, MA (US)
Filed on Jul. 21, 2022, as Appl. No. 17/870,336.
Application 17/870,336 is a division of application No. 15/758,394, granted, now 11,453,864, issued on Sep. 27, 2022, previously published as PCT/US2016/050396, filed on Sep. 6, 2016.
Claims priority of provisional application 62/215,424, filed on Sep. 8, 2015.
Prior Publication US 2023/0132569 A1, May 4, 2023
Int. Cl. C12N 9/22 (2006.01); A61K 38/00 (2006.01); C12N 15/11 (2006.01)

CPC C12N 9/22 (2013.01) [C12N 15/11 (2013.01); A61K 38/00 (2013.01); C12N 2310/20 (2017.05)]

8 Claims

1. A method, comprising;

a) providing:

i) a patient exhibiting at least one symptom of a virus infection; and

ii) a pharmaceutical composition comprising a Neisseria meningitidis Cas9 (NmeCas9) enzyme and a guide RNA (gRNA) sequence, wherein said gRNA lacks a transactivating CRISPR RNA (tracrRNA) sequence; and

b) administering said pharmaceutical composition to said patient under conditions such that at least one symptom of said virus infection is reduced.